Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.9.42 ↗At a glance
Klinische Studie (Phase III) in Investigative Ophthalmology & Visual Science, 2025. Written by Robert C Sergott and 10 co-authors. Institution: Departments of Ophthalmology and Neurology, Wills Eye Hospital; William H. Annesley, Jr., EyeBrain Center, Thomas Jefferson University, Philadelphia,…. Major MEDLINE topics: Optic Atrophy, Hereditary, Leber, Visual Acuity, Genetic Therapy, DNA, Mitochondrial. Cited 1 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
This exploratory analysis aimed to identify predictive factors of final best-corrected visual acuity (BCVA) in patients with Leber hereditary optic neuropathy (LHON) harboring the m.11778G>A mutation who received lenadogene nolparvovec gene therapy.
Methods
The following covariates were individually evaluated as possible factors associated with improved final BCVA: age, gender, timing of treatment, baseline BCVA value, and baseline optical coherence tomography (OCT) parameters. Univariate analyses were performed from three phase 3 studies (RESCUE, REVERSE, and REFLECT), using BCVA at 1.5 years post-treatment as the dependent variable.
Results
In 113 eyes treated at least 6 months after disease onset, the covariates statistically significantly associated with an improvement in final BCVA after having reached a nadir were thicker OCT measurements at baseline-specifically, outer segments of the macular ganglion cell layer (GCL) (superior, temporal, inferior, and nasal) and retinal nerve fiber layer (RNFL) quadrants (superior, inferior, and nasal) (P < 0.05). The largest effects were observed in the thickness of the superior outer GCL segments at baseline (-0.28 logMAR; 95% confidence interval [CI], -0.41 to -0.16) and temporal outer GCL segments at baseline (-0.26 logMAR; 95% CI, -0.38 to -0.13; both P
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Departments of Ophthalmology and Neurology, Wills Eye Hospital; William H. Annesley, Jr., EyeBrain Center, Thomas Jefferson University, Philadelphia, Pennsylvania, United States.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, Italy.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia, United States.
- Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
- Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom.
Cite
APA
Sergott, R. C., Carelli, V., Newman, N. J., Biousse, V., Yu-Wai-Man, P., Vignal-Clermont, C., Josse, C., Taiel, M., Sahel, J. A., Barboni, P., & LHON Study Group (2025). Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.9.42
Vancouver
Sergott RC, Carelli V, Newman NJ, Biousse V, Yu-Wai-Man P, Vignal-Clermont C, et al. Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.9.42
BibTeX
@article{Sergott2025,
author = {Sergott, Robert C and Carelli, Valerio and Newman, Nancy J and Biousse, Valérie and Yu-Wai-Man, Patrick and Vignal-Clermont, Catherine and Josse, Constant and Taiel, Magali and Sahel, José-Alain and Barboni, Piero and LHON Study Group, LHON Study Group},
title = {Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.9.42}
}
EUVIMED